Health Care

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022

/ / Health Care /

February 9, 2023 – Abbvie Inc. (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022. reported Q4 adjusted earnings  of $3.60 per diluted share, Analysts polled by Capital IQ expected $3.58. Revenue for the quarter ended Dec. 31 was $15.12 billion, Analysts surveyed by Capital IQ expected $15.30 billion. For the full year of 2023, the company is expecting adjusted earnings of $10.70 to $11.10 per diluted share. Analysts polled by Capital IQ are expecting $11.68. AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.1 Percent on an Operational Basis。 Reports Fourth-Quarter Diluted EPS of $1.38 on a GAAP Basis, a decrease […]

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022 Read Post »

Abbott (NYSE:ABT) Agreed to acquire Cardiovascular Systems for $890 million

/ / Health Care /

Shares rose 47 percent to $19.58 in early trading after Abbott (NYSE:ABT) agreed to buy Cardiovascular Systems (CSII) for $890 million, or $20 per share, MarketWatch reported. Termao Cardiovascular Systems is a leader in percutaneous atherectomy of transluminal plaques, a minimally invasive treatment for plaque buildup in the arteries. Abbott said the deal’s impact on its recently issued 2023 EPS guidance is neutral.

Abbott (NYSE:ABT) Agreed to acquire Cardiovascular Systems for $890 million Read Post »

GSK plc (NYSE:GSK) Sales grew 19% YoY to £29.3 billion in 2022

/ / Health Care /

1 February 202 GSK plc (NYSE:GSK)  delivers strong 2022 performance with full year sales of £29.3 billion。 +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations。 Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions。 Specialty Medicines £11.3 billion +37% AER, +29% CER; HIV +20% AER, +12% CER; Oncology +23% AER, +17% CER; Immuno-inflammation and other specialty +29% AER +20% CER; COVID-19 solutions (Xevudy) sales £2.3 billion。 Vaccines £7.9 billion +17% AER, +11% CER; Shingrix £3 billion +72% AER, +60% CER。 Total continuing operating margin 21.9%. Total EPS 371.4p > 100% primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business. Total continuing EPS 110.8p +34% AER, +18% CER。 Adjusted operating margin 27.8%. Adjusted operating profit growth +26% AER, +14% CER. This included a decline in growth from COVID-19

GSK plc (NYSE:GSK) Sales grew 19% YoY to £29.3 billion in 2022 Read Post »

Astrazeneca Plc(NASDAQ:AZN)：Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure

/ / Health Care /

According to Astrazeneca Plc (NASDAQ: AZN) official WeChat message, Andatang (generic name: dapagliflozin) has been approved in the European Union, expanding the indication for the treatment of heart failure with reduced ejection fraction (HFrEF) to cover patients with the entire range of left ventricular ejection fraction (LVEF), including mild and reserved heart failure (HFmrEF, HFpEF).

Astrazeneca Plc(NASDAQ:AZN)：Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure Read Post »

Amgen Inc. (NASDAQ:AMGN): The acquisition of Horizon Therapeutics is expected to be completed in the first half of the year

/ / Health Care /

On February 6, Amgen Inc.  (NASDAQ:AMGN) announced its fourth quarter and full year 2022 financial results. For the fourth quarter of 2022, the Company generated total revenue of $6.8 billion and GAAP earnings per share of $3.00, and for the full year 2022, total revenue of $26.3 billion and GAAP earnings per share of $12.11. Amgen said it expects to complete the acquisition of Horizon Therapeutics in the first half of this year.

Amgen Inc. (NASDAQ:AMGN): The acquisition of Horizon Therapeutics is expected to be completed in the first half of the year Read Post »

Scroll to Top